Przejdź do zawartości
Merck
  • Simultaneous determination of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in rat and human plasma by high-performance liquid chromatography.

Simultaneous determination of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in rat and human plasma by high-performance liquid chromatography.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (2003-12-04)
Hea-Young Cho, Tae-Jin Jeong, Yong-Bok Lee
ABSTRAKT

A rapid, selective and sensitive high-performance liquid chromatography (HPLC) method was developed and validated for the simultaneous determination of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid (HTB), in rat and human plasma. HPLC analysis was carried out using a 5-microm particle size, C18-bonded silica column and acetonitrile-methanol-water (25:10:65, v/v/v) as the mobile phase and UV detection at 234 nm. Furosemide was used as the internal standard. The method involved extraction with an acetonitrile-chloroform mixture (60:40, v/v) and evaporation to dryness with nitrogen stream. The chromatograms showed good resolution and sensitivity and no interferences by plasma constituents. The mean absolute recovery for human plasma was 93.5 +/- 4.2% for triflusal and 98.5 +/- 3.1% for HTB. The lower limits of quantification of triflusal and HTB in human plasma were 20 and 100 ng/ml, respectively. The calibration curves in human plasma were linear over the concentration range 0.02-5.0 microg/ml for triflusal and 0.1-200.0 microg/ml for HTB with correlation coefficients greater than 0.999 and with inter- or intra-day coefficients of variation (CV) not exceeding 10.0%. This assay procedure was applied to the study of metabolite pharmacokinetics of triflusal and HTB in rat and human.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Triflusal impurity B, European Pharmacopoeia (EP) Reference Standard